Argenx

145 articles with Argenx

• 

  FDA Action Alert: Biogen/Ionis, Cidara and Incyte

  3/20/2023

  An advisory committee will meet March 22 to discuss the fate of Biogen and Ionis’ ALS hopeful tofersen. For that and more, see inside.

• argenx Announces Annual General Meeting of Shareholders on May 2, 2023

  3/17/2023

  argenx SE announced that an Annual General Meeting of shareholders will be held at 12:00 PM CET on Tuesday, May 2, 2023 at Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.

• argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis

  3/15/2023

  argenx (Euronext & Nasdaq: ARGX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for VYVGART® (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody positive1.

• argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update

  3/2/2023

  argenx reported financial results for the full year 2022 and provided a fourth quarter business update.

• argenx Announces Planned Transition of Chief Operating Officer

  3/2/2023

  argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Karen Massey will join argenx as Chief Operating Officer, effective March 13, 2023.

• argenx Appoints Steve Krognes to Board of Directors

  2/27/2023

  argenx SE announced that during the extraordinary general meeting of shareholders held at 12:00pm CET, Steve Krognes was appointed as a non-executive director to its Board of Directors.

• argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023

  2/23/2023

  argenx announced that it will host a conference call and audio webcast on Thursday, March 2, 2023 at 2:30 pm CET to discuss its full year 2022 financial results and provide a fourth quarter business update.

• argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

  1/16/2023

  argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.

• argenx to Present at 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT.

• argenx Appoints Ana Cespedes to Board of Directors

  12/12/2022

  argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors.

• argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia

  12/10/2022

  argenx SE announced that data from its Phase 3 ADVANCE trial will be presented during the plenary session at the 64th American Society of Hematology Annual Meeting & Exposition in New Orleans, LA.

• argenx Enters Into Agreement To Acquire Priority Review Voucher

  11/30/2022

  argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced an agreement to acquire a U.S. Food and Drug Administration Priority Review Voucher for $102 million.

• 

  Argenx Scores Priority Review for Generalized Myasthenia Gravis Therapeutic

  11/22/2022

  The FDA granted argenx Priority Review status for the company’s BLA for SC efgartigimod for generalized myasthenia gravis. 

• argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

  11/22/2022

  argenx SE announced the U.S. Food and Drug Administration has accepted for priority review a Biologics License Application for SC efgartigimod for the treatment of adult patients with generalized myasthenia gravis.

• argenx Reports Third Quarter 2022 Financial Results and Provides Business Update

  10/27/2022

  argenx SE announced its third quarter 2022 financial results and provided a business update and outlook for the remainder of the year.

• argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022

  10/20/2022

  argenx announced that it will host a conference call and audio webcast on Thursday, October 27, 2022 at 2:30 pm CET to discuss its third quarter 2022 financial results and provide a business update.

• argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings

  9/21/2022

  argenx SE announced the presentation of new data from its neuromuscular franchise at the American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting and the Myasthenia Gravis Foundation of America Scientific Session, both being held in Nashville, TN.

• argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis

  9/21/2022

  argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the submission of a Biologics License Application to the U.S. Food and Drug Administration for SC efgartigimod for the treatment of generalized myasthenia gravis in adult patients.

• argenx Appoints Camilla Sylvest to Board of Directors

  9/8/2022

  argenx announced that during the extraordinary general meeting of shareholders held at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors.

• argenx to Present at Wells Fargo Healthcare Conference - Aug 31, 2022

  8/31/2022

  argenx announced that members of management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 8:00 a.m. E.T. in Boston, MA.